Evidence map›Paper›PMID 40290204›Full record

ArticleJournal of global infectious diseases

Evaluating Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Influenza: A Sensitivity Analysis Based on Information Theory and Causal Inference.

Fenny Ong, Geert Molenberghs, Andrea Callegaro, Wim Van Der Elst, Geert Verbeke, Florian Stijven, Ingrid Van Keilegom, Ariel Alonso Abad

Abstract read
In one paragraph

Article in Journal of global infectious diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fenny OngI-BioStat, Universiteit Hasselt, Diepenbeek, Belgium.
Geert MolenberghsI-BioStat, Universiteit Hasselt, Diepenbeek, Belgium.
Andrea CallegaroGSK Vaccines, Rixensart, Belgium.
Wim Van Der ElstThe Janssen Pharmaceutical Companies of Johnson and Johnson, Beerse, Belgium.
Geert VerbekeI-BioStat, KU Leuven, Leuven, Belgium.
Florian StijvenI-BioStat, KU Leuven, Leuven, Belgium.
Ingrid Van KeilegomORSTAT, KU Leuven, Leuven, Belgium.
Ariel Alonso AbadI-BioStat, KU Leuven, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Identifying hemagglutination inhibition (HI) antibody titers as a key immune correlate of protection (CoP) is crucial for developing, licensing, and monitoring the ongoing effectiveness of new influenza vaccines. Using a new statistical methodology, we explored the link between an inactivated quadrivalent influenza vaccine's impact on HI antibody titers and its effectiveness against A/H1N1-associated influenza illness. Methods: We utilized data from a phase 3, observer-blind, randomized, controlled trial in children aged 6-35 months to assess HI antibody titers as an immune CoP. The assessment used a statistical method developed within a causal inference framework and a new information-theoretic metric of surrogacy, the so-called individual causal association (ICA). Results: The 75% and 85% uncertainty intervals of the ICA are 0.5511-0.8282 and 0.3632-0.8684, respectively, indicating a substantial reduction in the uncertainty about the vaccine's effect on the absence of infection when its impact on the HI antibody titers is known. Conclusions: The evaluation yielded evidence supporting the validity of HI antibody titers as a CoP for influenza infection.

Indexed as

Causal inferencecorrelate of protectionhemagglutination inhibition antibody titerinformation theoryreverse transcription-polymerase chain reaction-confirmed influenzasurrogate

Identifiers

PMID40290204
PMCPMC12021349

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.